Argos' senior management has extensive pharmaceutical and biotechnology
industry experience including the clinical development, regulatory approval
and commercial introduction of oncology products, as well as the manufacturing
scale-up and launch of "blockbuster" products.
G. Dederick, Jr., M.B.A.
||Chairman, CEO and President
|Jeffrey D. Abbey, M.B.A., J.D.
||Vice President, Business Development
|Lothar H. Finke, M.D.
||Vice President, Clinical Development
|Frederick M. Miesowicz, Ph.D.
||Vice President, Manufacturing and Process Development
|Charles A. Nicolette, Ph.D.
||Vice President, Research and Development
|Timothy W. Trost, C.P.A.
||Vice President, Chief Financial Officer
||Vice President, Quality Assurance and Regulatory Affairs
Clint G. Dederick, Jr.
Chairman of the Board, CEO and President
Clint Dederick brings over 30 years of experience in the pharmaceutical
and biotechnology industries to Argos Therapeutics. He has served as
chairman of the board since the company’s inception.
Dederick was group director, venture projects, of Senmed Medical Ventures
for 15 years
prior to becoming CEO and president of Argos Therapeutics
in 2002. He also served on the boards of several companies during his
joining Senmed, Dederick worked with Praxis Biologics, Inc., Seragen,
Inc., and Collaborative Research, Inc. He also worked with Eli Lilly & Co.,
where he was engaged with a variety of domestic and international assignments
over a period of ten years. Dederick’s academic background includes
an undergraduate degree from the University of Delaware in biology and
chemistry, and a M.B.A. from the University of Virginia Darden School.
return to top
Jeffrey D. Abbey, M.B.A., J.D.
Vice President, Business Development
Jeffrey Abbey joined Argos Therapeutics in September 2002. Before
joining Argos, Abbey was Vice President of Business Development and Finance
for Internet Appliance Network (IAN), a venture-backed information technology
company based in New York City. Prior to joining IAN, he was a partner in Ehrenreich
Eilenberg and Krause, a boutique corporate law firm, where he acted as business
counsel for a number of life sciences and other emerging technology companies.
Abbey has extensive experience in structuring and negotiating licenses, joint
ventures and other technology transfer agreements, as well as mergers, acquisitions
and financing transactions. He holds an A.B. in Mathematical Economics from Brown
University and received an M.B.A. and J.D. from the University of Virginia.
return to top
Lothar H. Finke, M.D.
Vice President of Clinical Development
Lothar Finke, M.D., joined Argos Therapeutics to lead clinical development efforts
for a broad range of therapies. Dr. Finke has nine years of biotech oncology
experience in the pharmaceutical industry - both in Europe and the United
States. Additionally, he has six years of clinical experience in surgical oncology
and 10 years of experience in molecular and cell-biology.
Prior to joining Argos, Dr. Finke worked for a number of companies, including
EMD Pharmaceuticals, Lexigen Pharmaceuticals, and Merck KGaA. Academically, Dr.
Finke worked at the Max Delbrueck Center for Molecular Medicine, the Basel Institute
for Immunology, Ruprecht Karls University of Heidelberg, and Philipps University,
Marburg/Lahn, Germany. As part of his industry experience, he is trained and
experienced in regulatory affairs, drug safety, clinical development relevant
to Europe, the United States, Canada, and Japan.
Dr. Finke received both his medical degree and cellbiology doctorate from Philipps
University of Marburg in Lahn, Germany.
return to top
Frederick M. Miesowicz, Ph.D.
Vice President, Manufacturing and Process Development
Frederick Miesowicz joined Argos Therapeutics in
May 2003. Prior to this, Miesowicz was the Vice President of U.S.
Operations for Gamida-Cell, a stem cell company. He was Senior Vice President
Hybridon Specialty Products. He served as Senior Vice President of Scientific
Affairs at Cellcor from 1992 to 1995 and as Vice President and General
Manager of Cellcor, a subsidiary of Cytogen Inc., from 1995 to 1998,
where he directed all operations related to Cellcor’s cellular
immunotherapy programs. Miesowicz has an extensive background in
and medical devices. Prior to joining Cellcor, he managed the U.S. and
European SteriCell Division of Terumo Medical Corporation after it was
acquired from DuPont, and was with E.I. DuPont de Nemours & Company
for over 14 years managing both immunotherapy and immunodiagnostic R&D
groups. He holds a BS degree in Chemistry from Siena College and received
a Ph.D. in Chemistry from Harvard University.
return to top
Charles A. Nicolette, Ph.D.
Vice President, Research and Development
Charles Nicolette joined Argos Therapeutics in August 2003.
Nicolette has extensive experience in the field of cancer vaccines
and is the inventor on dozens of patent applications and issued patents
relating to vaccine development for cancer and infectious diseases. He
was formerly the Director of Antigen Discovery at Genzyme Molecular Oncology
where he developed SPHERE technology, the subject of one of the largest
biotechnology deals ever done in the field of tumor antigen discovery.
He is an expert in cellular immunology and brings substantial immunological
sophistication to Argos. Nicolette received his Ph.D. in biochemistry
and cellular and developmental biology from the State University of New
York at Stony Brook, completing his doctoral dissertation and post-doctoral
fellowship at Cold Spring Harbor Laboratory.
return to top
Timothy W. Trost, CPA
Vice President & Chief Financial Officer
Timothy Trost joined Argos Therapeutics in July 2002.
Prior to joining Argos, Trost most recently served as senior vice
president & chief
financial officer of InteCardia, Inc., a venture-backed cardiology
development firm sold to Syncor International (NASDAQ: SCOR) in August
to InteCardia, he served as senior vice president of corporate development
and later as executive vice president and chief financial officer of
Coastal Physician Group, Inc. (NYSE: DR), a contract provider of emergency
physicians. Prior to that, Trost served as vice president of finance
/ controller of Morganite North America, Inc., the US holding company
for The Morgan Crucible Company plc (London exchange). He began his professional
career with a total of twelve years (in four offices) at the international
accounting and consulting firm of Price Waterhouse. Trost holds
in accounting from the University of Illinois at Urbana-Champaign and
is a Certified Public Accountant.
return to top
Vice President, Quality Assurance and Regulatory
As Vice President of Quality Assurance and Regulatory Affairs, Doug Winship
is responsible for directing and managing the preparation of regulatory
submissions for current and new products being developed by the company,
as well as interfacing with regulatory agencies and corporate partners
on quality, regulatory, technical and business issues. He is also responsible
for assuring that manufacturing and development operations within the
company comply with cGMP, cGLP and cGCP requirements as required by
regulatory agencies worldwide. Prior to joining Argos, Winship previously
officer at CEL-SCI Corp. and Curative Technologies, Inc., Earlier in
his career, Winship worked at Seapharm, Inc., Oxford Research International
Corp., Revlon Health Care Group and Schering Plough, Inc.
Additionally, Winship’s expertise includes regulatory affairs,
quality assurance, clinical development and trial management, clinical
development for cancers and infectious disease, and strategic planning.
Winship has been involved in over 35 INDs, 12 NDAs/PLAs and 6 ANDAs
for drug and biological products in a number of therapeutic areas including
cancer, wound healing, infectious diseases and cardiovascular diseases.
In addition, Winship has established Regulatory Affairs and Quality
departments at VC-backed companies, and managed the successful development
of SOP and documentation systems. He has coordinated submissions to
regulatory agencies and Ethics Committees in support of the conduct
of trials in
Canada, UK, Sweden, Belgium, Germany, Netherlands, Poland, Czech Republic,
and Israel. He has also set up and administered trials in United States,
Canada, Hungary, Poland, Czech Republic, Netherlands and Israel.
He received a B.S. in Chemistry from Upsala College in New Jersey.
return to top